Press Releases
GT Biopharma Announces Enrollment Of Patient 10 in GTB-3550 TriKE™ Phase I/II Clinical Trial
GT Biopharma's TriKE™ Interim Clinical Trial Results Presented At Innate Killer Summit 2021
GT Biopharma Announces Updated Interim GTB-3550 Trike™ Clinical Trial Results
GT Biopharma to Present at The Virtual 33rd Annual Roth Conference
GT Biopharma Announces Preclinical Results For Its ROR1 TriKE™ As A Treatment For Prostate Cancer
GT Biopharma Adds University of Wisconsin--Madison Carbone Cancer Center as Second Site in Ongoing Phase 1/2 Clinical Trial of GTB-3550 TriKE™, a Novel NK Cell Therapeutic Cancer Treatment
GT Biopharma Transfers TriKE™ Manufacturing To Cytovance Biologics In Preparation For Expanded And Multiple Liquid And Solid Tumor Clinical Trials
GT Biopharma Announces Closing of $23.7 Million Public Offering
GT Biopharma Announces Pricing of $23,650,000 Public Offering and Uplisting to The Nasdaq Capital Market
